Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dor BioPharma, a late-stage biopharmaceutical company, has expanded its collaboration with BurnsAdler Pharmaceuticals, as Dor's distributor of orBec to patients suffering from acute gastrointestinal graft-versus-host disease in Canada via the special access program.
Subscribe to our email newsletter
The special access program (SAP) provides access to non-marketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable or are unavailable.
The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radio-pharmaceutical products not approved for sale in Canada. BurnsAdler and Dor will share revenues generated by sales of orBec through the SAP.
BurnsAdler is a specialty pharmaceutical company based in North Carolina that is also collaborating with Dor in Latin America.
Bryan Somerville, president of BurnsAdler, said: “We are very excited to be able to expand our existing relationship with Dor to now include Canada. We are looking forward to making this investigational therapy available in Canada and Latin America and to continuing to collaborate with Dor on these important named patient programs.”